On September 21, 2020, Inflazome announced that it had reached a share purchase agreement with Roche. They received an advance payment of 380million euros and were eligible to achieve certain predetermined goals and receive additional payments.

Inflazome is a biotechnology company and a leader in the development of inflammasome inhibitors, dedicated to the development of oral NLRP3 inflammasome inhibitors to treat various clinical inflammatory diseases. From Parkinson's disease and Alzheimer's disease to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH, inflammasomes are thought to cause many chronic inflammations. Inflazome has a series of orally available small molecule NLRP3 inhibitors, among which the leading candidate molecule has successfully completed phase I clinical trials and some high-potential early projects.

This acquisition gives Roche full ownership of Inflazome's entire product, which consists of clinical and preclinical oral small molecule NLRP3 inhibitors. Roche plans to further develop NLPR3 inhibitors in various indications with unmet medical needs.